611 related articles for article (PubMed ID: 27571885)
21. IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas.
Leeper HE; Caron AA; Decker PA; Jenkins RB; Lachance DH; Giannini C
Oncotarget; 2015 Oct; 6(30):30295-305. PubMed ID: 26210286
[TBL] [Abstract][Full Text] [Related]
22. Concurrent and Adjuvant Temozolomide for Newly Diagnosed Grade III Gliomas without 1p/19q Co-deletion: A Randomized, Open-Label, Phase 2 Study (KNOG-1101 Study).
Hwang K; Kim TM; Park CK; Chang JH; Jung TY; Kim JH; Nam DH; Kim SH; Yoo H; Hong YK; Kim EY; Lee DE; Joo J; Kim YJ; Choe G; Choi BS; Kang SG; Kim JH; Kim CY
Cancer Res Treat; 2020 Apr; 52(2):505-515. PubMed ID: 31671938
[TBL] [Abstract][Full Text] [Related]
23. Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide.
Wick W; Roth P; Hartmann C; Hau P; Nakamura M; Stockhammer F; Sabel MC; Wick A; Koeppen S; Ketter R; Vajkoczy P; Eyupoglu I; Kalff R; Pietsch T; Happold C; Galldiks N; Schmidt-Graf F; Bamberg M; Reifenberger G; Platten M; von Deimling A; Meisner C; Wiestler B; Weller M;
Neuro Oncol; 2016 Nov; 18(11):1529-1537. PubMed ID: 27370396
[TBL] [Abstract][Full Text] [Related]
24. Neoadjuvant chemotherapy may optimize the extent of resection of World Health Organization grade II gliomas: a case series of 17 patients.
Blonski M; Pallud J; Gozé C; Mandonnet E; Rigau V; Bauchet L; Fabbro M; Beauchesne P; Baron MH; Fontaine D; Peruzzi P; Darlix A; Duffau H; Taillandier L
J Neurooncol; 2013 Jun; 113(2):267-75. PubMed ID: 23479036
[TBL] [Abstract][Full Text] [Related]
25. Radiotherapy versus radiotherapy combined with temozolomide in high-risk low-grade gliomas after surgery: study protocol for a randomized controlled clinical trial.
Wang J; Wang Y; He Y; Guan H; He L; Mu X; Peng X
Trials; 2019 Nov; 20(1):641. PubMed ID: 31752981
[TBL] [Abstract][Full Text] [Related]
26. Phase II study of protracted daily temozolomide for low-grade gliomas in adults.
Kesari S; Schiff D; Drappatz J; LaFrankie D; Doherty L; Macklin EA; Muzikansky A; Santagata S; Ligon KL; Norden AD; Ciampa A; Bradshaw J; Levy B; Radakovic G; Ramakrishna N; Black PM; Wen PY
Clin Cancer Res; 2009 Jan; 15(1):330-7. PubMed ID: 19118062
[TBL] [Abstract][Full Text] [Related]
27. Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome.
Kaloshi G; Benouaich-Amiel A; Diakite F; Taillibert S; Lejeune J; Laigle-Donadey F; Renard MA; Iraqi W; Idbaih A; Paris S; Capelle L; Duffau H; Cornu P; Simon JM; Mokhtari K; Polivka M; Omuro A; Carpentier A; Sanson M; Delattre JY; Hoang-Xuan K
Neurology; 2007 May; 68(21):1831-6. PubMed ID: 17515545
[TBL] [Abstract][Full Text] [Related]
28. Dynamic history of low-grade gliomas before and after temozolomide treatment.
Ricard D; Kaloshi G; Amiel-Benouaich A; Lejeune J; Marie Y; Mandonnet E; Kujas M; Mokhtari K; Taillibert S; Laigle-Donadey F; Carpentier AF; Omuro A; Capelle L; Duffau H; Cornu P; Guillevin R; Sanson M; Hoang-Xuan K; Delattre JY
Ann Neurol; 2007 May; 61(5):484-90. PubMed ID: 17469128
[TBL] [Abstract][Full Text] [Related]
29. "One week on-one week off": efficacy and side effects of dose-intensified temozolomide chemotherapy: experiences of a single center.
Galldiks N; Berhorn T; Blau T; Dunkl V; Fink GR; Schroeter M
J Neurooncol; 2013 Apr; 112(2):209-15. PubMed ID: 23299464
[TBL] [Abstract][Full Text] [Related]
30. Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial.
van den Bent MJ; Klein M; Smits M; Reijneveld JC; French PJ; Clement P; de Vos FYF; Wick A; Mulholland PJ; Taphoorn MJB; Lewis J; Weller M; Chinot OL; Kros JM; de Heer I; Verschuere T; Coens C; Golfinopoulos V; Gorlia T; Idbaih A
Lancet Oncol; 2018 Sep; 19(9):1170-1179. PubMed ID: 30115593
[TBL] [Abstract][Full Text] [Related]
31. Multicenter phase II study of temozolomide and myeloablative chemotherapy with autologous stem cell transplant for newly diagnosed anaplastic oligodendroglioma.
Thomas AA; Abrey LE; Terziev R; Raizer J; Martinez NL; Forsyth P; Paleologos N; Matasar M; Sauter CS; Moskowitz C; Nimer SD; DeAngelis LM; Kaley T; Grimm S; Louis DN; Cairncross JG; Panageas KS; Briggs S; Faivre G; Mohile NA; Mehta J; Jonsson P; Chakravarty D; Gao J; Schultz N; Brennan CW; Huse JT; Omuro A
Neuro Oncol; 2017 Oct; 19(10):1380-1390. PubMed ID: 28472509
[TBL] [Abstract][Full Text] [Related]
32. Nitrosourea-based chemotherapy for low grade gliomas failing initial treatment with temozolomide.
Kaloshi G; Sierra del Rio M; Ducray F; Psimaras D; Idbaih A; Laigle-Donadey F; Taillibert S; Houillier C; Dehais C; Omuro A; Sanson M; Delattre JY; Hoang-Xuan K
J Neurooncol; 2010 Dec; 100(3):439-41. PubMed ID: 20464625
[TBL] [Abstract][Full Text] [Related]
33. Prolonged administration of temozolomide in adult patients with anaplastic glioma.
Freyschlag CF; Smolczyk DR; Janzen E; Schmieder K; Thomé C; Lohr F; Wenz F; Weiss C; Tuettenberg J; Seiz M
Anticancer Res; 2011 Nov; 31(11):3873-7. PubMed ID: 22110212
[TBL] [Abstract][Full Text] [Related]
34. Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma.
Omuro A; Chan TA; Abrey LE; Khasraw M; Reiner AS; Kaley TJ; Deangelis LM; Lassman AB; Nolan CP; Gavrilovic IT; Hormigo A; Salvant C; Heguy A; Kaufman A; Huse JT; Panageas KS; Hottinger AF; Mellinghoff I
Neuro Oncol; 2013 Feb; 15(2):242-50. PubMed ID: 23243055
[TBL] [Abstract][Full Text] [Related]
35. Temozolomide three weeks on and one week off as first line therapy for patients with recurrent or progressive low grade gliomas.
Tosoni A; Franceschi E; Ermani M; Bertorelle R; Bonaldi L; Blatt V; Brandes AA
J Neurooncol; 2008 Sep; 89(2):179-85. PubMed ID: 18431544
[TBL] [Abstract][Full Text] [Related]
36. Correlation of Molecular Markers in High Grade Gliomas with Response to Chemo-Radiation.
Khurana R; Rath S; Singh HB; Rastogi M; Nanda SS; Chauhan A; Kaif M; Hussain N
Asian Pac J Cancer Prev; 2020 Mar; 21(3):755-760. PubMed ID: 32212804
[TBL] [Abstract][Full Text] [Related]
37. IDH mutation status trumps the Pignatti risk score as a prognostic marker in low-grade gliomas.
Etxaniz O; Carrato C; de Aguirre I; Queralt C; Muñoz A; Ramirez JL; Rosell R; Villà S; Diaz R; Estival A; Teixidor P; Indacochea A; Ahjal S; Vilà L; Balañá C
J Neurooncol; 2017 Nov; 135(2):273-284. PubMed ID: 28884377
[TBL] [Abstract][Full Text] [Related]
38. Prospective evaluation of radiotherapy with concurrent and adjuvant temozolomide in children with newly diagnosed diffuse intrinsic pontine glioma.
Jalali R; Raut N; Arora B; Gupta T; Dutta D; Munshi A; Sarin R; Kurkure P
Int J Radiat Oncol Biol Phys; 2010 May; 77(1):113-8. PubMed ID: 19647954
[TBL] [Abstract][Full Text] [Related]
39. Prognostic factors and survival in a prospective cohort of patients with high-grade glioma treated with carmustine wafers or temozolomide on an intention-to-treat basis.
Catalán-Uribarrena G; Bilbao-Barandica G; Pomposo-Gaztelu I; Undabeitia-Huertas J; Ruiz de Gopegui-Ruiz E; Galbarriatu-Gutiérrez L; Canales-Llantada M; Aurrecoechea-Obieta J; Igartua-Azkune A; Carbayo-Lozano G
Acta Neurochir (Wien); 2012 Feb; 154(2):211-22; discussion 222. PubMed ID: 22002506
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of protracted dose-dense temozolomide in patients with recurrent high-grade glioma.
Abacioglu U; Caglar HB; Yumuk PF; Akgun Z; Atasoy BM; Sengoz M
J Neurooncol; 2011 Jul; 103(3):585-93. PubMed ID: 20878446
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
